Roche insists amylin obesity drug still valuable for patients who ‘don’t want side effects’

Roche and Zealand Pharma announced last month that their amylin analog petrelintide elicited a 9% placebo-controlled weight reduction at 42 weeks—falling far below analyst and investor expectations.